# US 2026/0083849 A1 · Modified t-cells for use in the treatment of bladder cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083849 A1
- Document ID: US20260083849A1
- Status: Published application
- Kind: A1
- Application number: 19/108,853
- Filed: 2023-09-07
- Published: 2026-03-26
- Earliest claimed: 2022-09-07
- Assignees: Uswm Ct, LLC
- Applicants: Uswm Ct, LLC
- Inventors: Stephen DAWE; Alejandro GARCIA-CONSUEGRA LÓPEZ-PICAZO; José María SARO SUAREZ
- Web page: https://patentgrep.com/patent/US20260083849A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/4268: {MAGE}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- A61K 2239/46: characterised by the cancer treated
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to a method of treating bladder cancer, and to a population of modified immunoresponsive cells expressing a heterologous TCR for use in such method.

## Claims

### Claim 1

A method of treating bladder cancer in an individual, comprising administering to the individual a population of modified T cells comprising a heterologous T-cell receptor (TCR) capable of binding to a peptide antigen of MAGE-A4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises administering a checkpoint inhibitor to the individual, optionally wherein the population of modified T cells and the checkpoint inhibitor are administered in the same line of therapy.

### Claim 3 (depends on 2)

The method of claim 2, wherein:
(a) administration of the checkpoint inhibitor begins before administration of the population of modified T cells, and continues after administration of the population of modified T cells; or
(b) administration of the checkpoint inhibitor begins at the same time as or after administration of the population of modified T cells, and continues after administration of the population of modified T cells.

### Claim 4 (depends on 2)

The method of claim 2, wherein the checkpoint inhibitor comprises a Programmed Death-1 (PD-1) axis binding antagonist, optionally pembrolizumab.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises administering an additional anti-cancer therapy to the individual, optionally wherein:
(a) population of modified T cells and the additional anti-cancer therapy are administered in the same line of therapy; and/or
(b) the additional anti-cancer therapy is a chemotherapy.

### Claim 6 (depends on 5)

The method of claim 5, wherein:
(a) administration of the additional anti-cancer therapy begins before administration of the population of modified T cells, and continues after administration of the population of modified T cells; or
(b) administration of the additional anti-cancer therapy begins at the same time as or after administration of the population of modified T cells, and continues after administration of the population of modified T cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bladder cancer is relapsed bladder cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the bladder cancer has relapsed following curative intent treatment for locally advanced bladder cancer, optionally wherein:
(a) the curative intent treatment comprises surgical resection and/or radiation therapy; and/or
(b) the curative intent treatment comprises systemic therapy.

### Claim 9 (depends on 7)

The method of claim 7, wherein:
(a) the method comprises administering a checkpoint inhibitor to the individual and administration of the checkpoint inhibitor begins at the same time as or after administration of the population of modified T cells and continues after administration of the population of modified T cells; and/or
(b) the method comprises administering an additional anti-cancer therapy to the individual and administration of the additional anti-cancer therapy begins at the same time as or after administration of the population of modified T cells and continues after administration of the population of modified T cells, optionally wherein the additional anti-cancer therapy is a chemotherapy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the individual has not previously been treated for the bladder cancer, optionally wherein the bladder cancer is newly metastatic or unresectable locally advanced bladder cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein:
(a) the method comprises administering a checkpoint inhibitor to the individual, and administration of the checkpoint inhibitor begins before or at the same time as administration of the population of modified T cells and continues after administration of the population of modified T cells; or
(b) the method comprises administering an additional anti-cancer therapy to the individual, and administration of the additional anti-cancer therapy begins before or at the same time as administration of the population of modified T cells and continues after administration of the population of modified T cells, optionally wherein the additional anti-cancer therapy is a chemotherapy.

### Claim 12 (depends on 1)

The method of claim 1, wherein:
(a) the population of modified T cells is administered as soon as possible after diagnosis of the bladder cancer; and/or
(b) the population of modified T cells is administered as a single dose.

### Claim 13 (depends on 1)

The method of claim 1, wherein:
(a) the heterologous TCR binds to GVYDGREHTV (SEQ ID NO: 1) in complex with an HLA molecule;
(b) the heterologous TCR comprises an alpha chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2 and a beta chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3; and/or
(c) the modified T cell further comprises a heterologous CD8 co-receptor, optionally wherein the heterologous CD8 co-receptor is CD8α.

### Claim 14 (depends on 1)

The method of claim 1, wherein the modified T cells are autologous with respect to the individual; optionally wherein the method comprises producing the population by:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the individual;
(b) selecting T cells from the PBMCs; and
(c) modifying the selected T cells to express the heterologous TCR and optionally a heterologous CD8 co-receptor;
and further optionally wherein the bladder cancer is relapsed bladder cancer and wherein one or more of steps (a) to (c) are performed prior to relapse.

### Claim 15 (depends on 1)

A population of modified T cells comprising a heterologous T-cell receptor capable of binding to a peptide antigen of MAGE-A4, for use in the method of claim 1.
